The world is changing fast and to keep up you need local knowledge with global context.
By Janice Kew
(Bloomberg) – Johnson & Johnson’s coronavirus vaccine has been approved by South African regulators for general use days after President Cyril Ramaphosa said the country will get more than 30 million doses.
The South African Health Products Regulatory Authority has backed the single-shot candidate with conditions, spokesman Yuven Gounden said by phone on Thursday, without giving further detail.
The U.S. drugmaker’s vaccine has so far only been used in the country to inoculate health workers, and its approval is a boost to a national roll out that’s been hit by a series of delays. The regulator last month approved the shot developed by Pfizer Inc. and BioNTech SE, though AstraZeneca Plc’s has been spurned due to concern over its limited efficacy against a variant identified in the country late last year.
J&J agreed earlier this week to supply as many as 400 million doses to the African Union through the end of next year. The vaccine is seen as beneficial for Africa as in addition to being a single dose it can also be distributed at regular fridge temperatures, as opposed to the super-cold requirements vaccines made by Pfizer and Moderna Inc.
- Johnson & Johnson to supply 400 million Covid-19 shots to African Union
- SA backed right vaccine horse in J&J – With insights from The Wall Street Journal
- Vaccine rollout begins with J&J shot distributed over night
Cyril Ramaphosa: The Audio Biography
Listen to the story of Cyril Ramaphosa's rise to presidential power, narrated by our very own Alec Hogg.